NIAID Raises Awareness to Malaria-like Diseases in W. Africa

NIAID Now |

NIAID Raises Awareness to Malaria-like Diseases in W. Africa

Dengue, Zika, Chikungunya Viruses in Mali; Disease Likely Misdiagnosed

NIAID scientists and colleagues have identified dengue, Zika and chikungunya viruses in the West African country of Mali, where health care providers likely misdiagnose patients with illness from those viruses due to unavailable diagnostic tools. Because malaria is the most common fever-causing illness in rural sub-Saharan Africa, most medical workers presume patients with a fever have malaria. The primary cause of all four infectious diseases is a mosquito bite.

Records from the Malian Health Information System show that about one-third of all patient visits to health care facilities are related to malaria, with 2.37 million clinical cases.

A new study from NIAID’s Rocky Mountain Laboratories and the University of Sciences, Techniques and Technologies in Mali aims to help spread information to medical workers about the existence of the additional viral diseases. Ideally, circulating the information will help them obtain the necessary diagnostics.

The study, published in The American Journal of Tropical Medicine and Hygiene, involved 600 residents, 200 from each of the southern Malian communities of Soromba, Bamba and Banzana. The scientists detected antibodies to dengue virus in the blood of 77.2% of the residents tested; to Zika virus in 31.2%, and to chikungunya virus in 25.8%. They detected at least one of the three viruses in 84.9% of participants, meaning just 15.1% tested negative to any of the three viruses.

Evidence of the parasites that cause malaria was found in 44.5% of those tested. Unlike malaria, however, where most cases are found in children under age 14, residents over age 50 were most likely to have been exposed to dengue, Zika or chikungunya viruses. 

“Despite the high exposure risk to dengue virus in southern Mali, dengue fever cases have rarely been reported,” the researchers write. “This is likely due to the lack of diagnostic testing and the biased clinical focus on malaria in the region. Awareness of dengue virus as a cause of febrile illness needs to be urgently established in medical communities as an important public health measure.”

The scientists are hoping data from a more in-depth clinical study that just ended will provide additional details about the prevalence of these viruses in Mali. They also are planning to examine patients who have undiagnosed fevers to establish infection rates.

NIAID scientists are investigating dengue, Zika and chikungunya viruses to try and develop preventive and therapeutic treatment options, none of which exist.

Reference: S Bane, et alSeroprevalence of Arboviruses in a Malaria Hyperendemic Area in Southern MaliThe American Journal of Tropical Medicine and Hygiene DOI: 10.4269/ajtmh.23-0803 (2024).

Contact Information

Contact the NIAID Media Team.

301-402-1663
niaidnews@niaid.nih.gov

Search NIAID Blog

NIH Releases H5N1 Influenza Research Agenda

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has released its plan for advancing H5N1 influenza basic research and translating those findings into strategies and interventions that can benefit people.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

U.S. Clinical Trials Begin for Twice-Yearly HIV Prevention Injection

Two clinical trials have launched to examine a novel long-acting form of HIV pre-exposure prophylaxis (PrEP) in cisgender women and people who inject drugs. The mid-stage studies will assess the safety, acceptability, and pharmacokinetics (how a drug moves through the body) of lenacapavir, an antiretroviral drug administered by injection every six months. The studies are sponsored and funded by Gilead Sciences, Inc., and implemented through the HIV Prevention Trails Network (HPTN).

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Lucas Dos Santos Dias, Ph.D.

Section or Unit Name
Fungal Pathogenesis Section
Exclude from directory
Off
Section/Unit: Location
This Researcher/Clinician’s Person Page
Program Description

In the Fungal Pathogenesis Section, we use an integrated bench-to-bedside multidisciplinary approach encompassing immunology, mycology, and genetics to investigate protection against and susceptibility to pathogenic fungi. We evaluate large cohorts of patients with inherited or acquired susceptibility to fungal disease and study antifungal immune responses in vitro and in vivo in a variety of clinically relevant mouse models of fungal disease. Thus, we employ various immunological, biological, and imaging approaches to measure biological determinants of disease outcomes in humans and mice. Our research directly informs clinically actionable interventions, including developing targeted preventive and therapeutic interventions in at-risk patients.

Selected Publications

Woodring T, Dewey CN, Santos Dias LD, He X, Dobson HE, Wüthrich M, Klein B. Distinctive populations of CD4+T cells associated with vaccine efficacy. iScience. 2022 Aug 13;25(9):104934.

Kohn EM, Taira C, Dobson H, Dias LDS, Okaa U, Wiesner DL, Wüthrich M, Klein BS. Variation in Host Resistance to Blastomyces dermatitidis: Potential Use of Genetic Reference Panels and Advances in Immunophenotyping of Diverse Mouse Strains. mBio. 2022 Feb 22;13(1):e0340021.

Dos Santos Dias L, Dobson HE, Bakke BK, Kujoth GC, Huang J, Kohn EM, Taira CL, Wang H, Supekar NT, Fites JS, Gates D, Gomez CL, Specht CA, Levitz SM, Azadi P, Li L, Suresh M, Klein BS, Wüthrich M. Structural basis of Blastomyces Endoglucanase-2 adjuvancy in anti-fungal and -viral immunity. PLoS Pathog. 2021 Mar 18;17(3):e1009324.

Dobson HE, Dias LDS, Kohn EM, Fites S, Wiesner DL, Dileepan T, Kujoth GC, Abraham A, Ostroff GR, Klein BS, Wüthrich M. Antigen discovery unveils resident memory and migratory cell roles in antifungal resistance. Mucosal Immunol. 2020 May;13(3):518-529.

Rocke TE, Kingstad-Bakke B, Wüthrich M, Stading B, Abbott RC, Isidoro-Ayza M, Dobson HE, Dos Santos Dias L, Galles K, Lankton JS, Falendysz EA, Lorch JM, Fites JS, Lopera-Madrid J, White JP, Klein B, Osorio JE. Virally-vectored vaccine candidates against white-nose syndrome induce anti-fungal immune response in little brown bats (Myotis lucifugus). Sci Rep. 2019 May 1;9(1):6788.

Holanda RA, Muñoz JE, Dias LS, Silva LBR, Santos JRA, Pagliari S, Vieira ÉLM, Paixão TA, Taborda CP, Santos DA, Bruña-Romero O. Recombinant vaccines of a CD4+ T-cell epitope promote efficient control of Paracoccidioides brasiliensis burden by restraining primary organ infection. PLoS Negl Trop Dis. 2017 Sep 22;11(9):e0005927.

Visit PubMed for a complete publication list.

Major Areas of Research
  • AIRE-dependent mechanisms of antifungal immunity and protection from autoimmunity in mouse models of AIRE deficiency and in APECED patients 
  • Novel mechanism-based strategies to treat fungal disease and autoimmunity in APECED and STAT1 gain-of-function patients
  • Experimental models (mice) for the study of the mechanism of vaccine-induced immunity to Blastomyces and other fungal pathogens (Coccidioides, Candida, Histoplasma)
  • Cellular immunology
  • Fungal immunology

Novel Vaccine Concept Generates Immune Responses that Could Produce Multiple Types of HIV Broadly Neutralizing Antibodies

Using a combination of cutting-edge immunologic technologies, researchers have successfully stimulated animals’ immune systems to induce rare precursor B cells of a class of HIV broadly neutralizing antibodies (bNAbs). The findings, published today in Nature Immunology, are an encouraging, incremental step in developing a preventive HIV vaccine.   

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Age, Sex May Be Important to Consider in Assessing Tuberculosis Risk

Media Type
Article
Publish or Event Date
Research Institution
Harvard T.H. Chan School of Public Health
Short Title
Age, Sex May Be Important to Consider in Assessing Tuberculosis Risk
Content Coordinator

GPS-like System Shows Promise as HIV Vaccine Strategy to Elicit Critical Antibodies

Supercomputing Redesign of a COVID Monoclonal Antibody

Media Type
Article
Publish or Event Date
Research Institution
Vanderbilt University Medical Center
Short Title
Supercomputing Redesign of a COVID Monoclonal Antibody
Content Coordinator

US Geographic Region Results in Vastly Different Anal Cancer Risk for People with HIV

Media Type
Article
Publish or Event Date
Research Institution
Medical University of South Carolina
Short Title
US Geographic Region Results in Vastly Different Anal Cancer Risk for People with HIV
Content Coordinator

How E. coli Get the Power to Cause Urinary Tract Infections